The role of androgen receptor (AR) in breast cancer has been unveiled in succession for the past few years. In this study, we conducted a comprehensive analysis based on four online public databases of data from many previous studies. We found that the expression of AR is significantly related to age, histological grade, and subtype but not to lymph node status. The low expression level of AR is strongly associated with poor recurrence-free survival, especially with poor distance metastasis-free survival in luminal A patients, but inverse in HER2 (human epidermal growth factor receptor-2) enriched patients. AR might be a biomarker of chemosensitivity in the basal subtype. Besides, the expression of melanophilin (MLPH) is distinctly in accordance with that of AR. AR could play diverse roles in different subtypes of breast cancer.

中文翻译：

---

乳腺癌中雄激素受体的表达，临床病理特征和预后价值：使用公共数据库的生物信息学分析。

在过去的几年中，雄激素受体（AR）在乳腺癌中的作用已经陆续揭晓。在这项研究中，我们基于来自许多先前研究的数据的四个在线公共数据库进行了全面分析。我们发现，AR的表达与年龄，组织学等级和亚型显着相关，而与淋巴结状态无关。AR的低表达水平与不良的无复发生存密切相关，特别是与管腔A患者的较差的无远处转移生存有关，但与富含HER2（人类表皮生长因子受体2）的患者相反。AR可能是基底亚型化学敏感性的生物标志物。此外，黑色素蛋白（MLPH）显然与AR一致。AR在乳腺癌的不同亚型中可以发挥不同的作用。